StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences R&D by cost type

R&D by cost type — Clinical studies and outside services / other costs ($M) ($M)

QuarterlyAnnual

Gilead Sciences R&D by cost type: $2,372M in FY2025, up 0.9% from a year earlier.

Latest, FY2025
2,372
Period ended Dec 31, 2025
Change on a year earlier
+0.9%
2,352 in FY2024
History
13 years
Since FY2012
Sources
10
Documents cited below

Where the FY2025 figure comes from

“|| Clinical studies and other costs | 2,372 | 2,352 | 1 | %”

Source: Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗

Reported in Form 10-Q / 10-K MD&A Research and Development Expenses.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedR&D by cost type — Clinical studies and outside services / other costs ($M) ($M)Year on yearSource
FY2025Dec 31, 20252,372+0.9%Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗
FY2024Dec 31, 20242,352-6.4%Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗
FY2023Dec 31, 20232,514+16.1%Form 10-K (gild-20241231.htm, filed 2025-02-28) ↗
FY2022Dec 31, 20222,166–Form 10-K (gild-20231231.htm, filed 2024-02-23) ↗
FY2020Dec 31, 20202,317+32.4%Form 10-K (gild-20201231.htm, filed 2021-02-25) ↗
FY2019Dec 31, 20191,750+5.1%Form 10-K (gild-20201231.htm, filed 2021-02-25) ↗
FY2018Dec 31, 20181,665-11.5%Form 10-K (gild-20201231.htm, filed 2021-02-25) ↗
FY2017Dec 31, 20171,881-23.1%Form 10-K (a2019form10-k.htm, filed 2020-02-25) ↗
FY2016Dec 31, 20162,446+56.0%Form 10-K (a2018form10-k.htm, filed 2019-02-26) ↗
FY2015Dec 31, 20151,568-7.1%Form 10-K (a2017form10-k.htm, filed 2018-02-27) ↗
FY2014Dec 31, 20141,688+47.2%Form 10-K (a2016form10-k.htm, filed 2017-02-27) ↗
FY2013Dec 31, 20131,147+38.5%Form 10-K (a2015form10-k.htm, filed 2016-02-24) ↗
FY2012Dec 31, 2012828–Form 10-K (a2014form10-k.htm, filed 2015-02-25) ↗

Cite this data

StockData. (2026). Gilead Sciences R&D by cost type ($M), annual FY2012–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rd-clinical-studies

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.